Kristine Kucera, PA-C, MPAS, DHS

Expert dermatology physician assistants share how to select the appropriate therapy for your patient with plaque psoriasis in an expanding treatment landscape.

Selecting appropriate therapy in an evolving treatment landscape of plaque psoriasis 

In this series, dermatologists TJ Chao and Kristine Kucera delve into recent developments in plaque psoriasis treatment, including the emergence of TYK2 inhibitors. They highlight the evolving role of physician assistants in managing plaque psoriasis and discuss its recognition as a systemic disease. The conversation covers lab and monitoring requirements for TYK2 inhibitors like deucravacitinib, alongside a review of short- and long-term clinical trial data. Chao and Kucera offer insights into patient selection and the patient experience with oral systemic agents, providing guidance for selecting appropriate therapies in the expanding treatment landscape.

This summary was AI-generated and edited for clarity.

Videos

Selecting Appropriate Therapy in the Evolving Treatment Landscape of Plaque Psoriasis

TJ Chao and Kristine Kucera, PA’s share their insights into the patient experience with oral systemic agents for plaque psoriasis.

Patient experience with oral systemic treatments

Patient Experience With Oral Systemic Treatments

TJ Chao and Kristine Kucera, PA’s discuss the changing treatment algorithms of plaque psoriasis with the arrival of novel agents such as the TYK2 inhibitors. 

Impact of the expanding treatment landscape on the treatment algorithm of plaque psoriasis 

Impact of the Expanding Treatment Landscape on the Treatment Algorithm of Plaque Psoriasis

Advances practice providers in dermatology discuss the safety data on the novel TYK2 inhibitor deucravacitnib. 

Kristine Kucera, PA-C, MPAS, DHS

Articles